Flow Cytometry of Hematological Malignancies Flow cytometric analysis is often integral to the swift and accurate diagnosis of leukemias and lymphomas of the blood, bone marrow, and lymph nodes. However, in the fast-moving and expanding field of clinical hematology, in can be challenging to remain up to speed with the latest biological research and technological innovations. Flow Cytometry of Hematological Malignancies has been designed to provide all those working in hematological oncology with a practical, cutting-edge handbook, featuring clear and fully illustrated guidance on all aspects of cytometry’s role in diagnosis and analysis. This essential second edition includes:
Explorations of more than 70 antigens Full-color illustrations throughout New descriptions of recently discovered markers WHO classifications of hematological neoplastic diseases Helpful tips for result interpretation and analysis
Featuring all this and more, Flow Cytometry of Hematological Malignancies, Second Edition, is an invaluable resource for both trainee and experienced hematologists, hematopathologists, oncologists, and pathologists, as well as medical students and diagnostic lab technicians.
By:
Claudio Ortolani (Ospedale dell'Angelo Venice Italy)
Imprint: Wiley-Blackwell
Country of Publication: United States
Edition: 2nd edition
Dimensions:
Height: 279mm,
Width: 216mm,
Spine: 29mm
Weight: 1.474kg
ISBN: 9781119611257
ISBN 10: 1119611253
Pages: 464
Publication Date: 14 April 2021
Audience:
Professional and scholarly
,
Undergraduate
Replaced By: 9781394245147
Format: Hardback
Publisher's Status: Active
Foreword to the Second Edition xi by Michael J. Borowitz Foreword to the First Edition xii by Maryalice Stetler-Stevenson Foreword to the First Edition xiii by Bruno Brando Preface to the Second Edition xv Preface to the First Edition xvi Abbreviations xvii 1 Antigens 1 Clustered (CD) Antigens CD1 3 CD2 5 CD3 8 CD4 17 CD5 21 CD7 24 CD8 26 CD10 30 CD11b 35 CD11c 38 CD13 40 CD14 44 CD15 46 CD16 49 CD19 52 CD20 55 CD22 59 CD23 61 CD24 64 CD25 66 CD26 67 CD27 69 CD28 70 CD30 71 CD33 73 CD34 77 CD38 79 CD43 81 CD45 82 CD45 Isoforms 87 CD49 90 CD56 93 CD57 96 CD61 97 CD62L 98 CD64 99 CD65 101 CD66c 102 CD71 103 CD79 104 CD81 107 CD103 108 CD117 110 CD123 112 CD138 113 CD200 114 CD305 116 CD307 (IRTA) Antigen Family 117 CD371 118 Non clustered (or primarily known with other names) antigens Bcl‐2 Protein 119 Chemokines and Chemokine Receptors 121 CRLF2 128 Cytotoxic Proteins 129 HLA‐DR 130 Immunoglobulins 132 KIR, CD158 isoforms 136 Myeloperoxidase (MPO) 139 NG2 140 PCA‐1 141 ROR1 141 SLAM Molecules and SLAM‐associated Protein (SAP) 142 SOX11 144 T‐cell Receptor (TCR) 145 Terminal Deoxy‐nucleotidyl‐transferase (TdT) 148 Toll‐like Receptors (TLR) 150 VS38 151 ZAP‐70 152 2 Diseases 155 Myeloproliferative neoplasms 157 Chronic myeloid leukemia (CML) 157 Myeloproliferative neoplasms other than CML 160 Chronic neutrophilic leukemia (CNL) 160 Polycythemia vera (PV) 160 Primary myelofibrosis (PMF) 160 Essential thrombocythemia (ET) 160 Chronic eosinophilic leukemia (CEL) 161 Mastocytosis 162 Acute mast‐cell leukemia (AMCL) 162 Chronic mast‐cell leukemia (CMCL) 163 Myelomastocytic leukemia (MML) 163 Myelodysplastic/myeloproliferative neoplasms 164 Chronic myelomonocytic leukemia (CMML) 164 Other myelodysplastic/myeloproliferative neoplasms and related conditions 167 Juvenile myelomonocytic leukemia (JMML) 167 Atypical CML bcr/abl negative (ACML) 167 RAS‐associated autoimmune leukoproliferative disorder (RALD) 167 Myelodysplastic syndromes 168 Myeloid neoplasms with germline predisposition 171 Acute myeloid leukemias 172 AMLs with recurrent genetic anomalies 173 AMLs with chromosomal anomalies 173 AMLs with gene mutations 180 Relationships between genotype and phenotype in cases of AML not recognized as separate entities in WHO 2017 181 AMLs with myelodysplasia‐related changes (AML‐MRC) 182 AMLs not otherwise specified 182 AML with minimal differentiation 182 AML without maturation 183 AML with maturation 183 Acute myelomonocytic leukemia (AMMoL) 183 Acute monoblastic and monocytic leukemia (AMoL) 184 Pure erythroid leukemia (PEL) 185 Acute megakaryoblastic leukemia (AMKL) 186 Acute basophilic leukemia (ABL) 188 Myeloid proliferations associated with Down syndrome 188 Transient abnormal myelopoiesis (TAM) 189 AMLs in patients with Down syndrome 189 Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL) 189 Acute leukemias with ambiguous lineage attribution (ALAL) 192 Acute undifferentiated leukemias (AUL) 192 Mixed phenotype acute leukemias (MPAL) 192 Neoplastic diseases of B and T lymphatic precursors 194 B lymphoblastic leukemia/lymphoma, not otherwise specified (B‐ALL/LBLnos) 195 B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies 197 Relationships between genotype and phenotype in cases of B‐ALL not recognized as separate entities in WHO 2017 201 T lymphoblastic leukemia/lymphoma (T‐ALL/LBL) 202 Early T‐cell precursor lymphoblastic leukemia (ETP‐ALL) 205 NK lymphoblastic leukemia/lymphoma (NK‐ALL/LBL) 205 Neoplastic diseases of mature B cells 206 Chronic lymphocytic leukemia/small lymphocytic lymphoma (B‐CLL/SLL) 206 Familial B‐CLL 215 Richter syndrome 215 Monoclonal B‐cell lymphocytosis (MBL) 216 CLL‐like monoclonal B lymphocytosis 216 Non‐CLL‐like monoclonal B lymphocytosis 216 B‐cell prolymphocytic leukemia (B‐PLL) 216 Lymphoplasmacytic lymphoma (LPL) 218 Heavy chain disease (HCD) 221 γ heavy chain disease 222 μ heavy chain disease 222 α heavy chain disease 222 Hairy cell leukemia (HCL) 222 Hairy cell leukemia, variant (HCL‐v) 226 Hairy cell leukemia, Japanese variant (HCL‐J) 227 Splenic diffuse red pulp lymphoma (SDRPL) 227 Marginal zone lymphomas (MZL) 228 Nodal marginal zone lymphoma (NMZL) 229 Splenic marginal zone lymphoma (SMZL) 230 Extranodal marginal zone lymphoma (EMZL/MALToma) 232 Clonal B‐cell lymphocytosis with MZL‐like phenotype (CBL‐MZ) 233 Follicular lymphoma (FCL) 234 Testicular follicular lymphoma 237 Duodenal type follicular lymphoma 237 Pediatric type follicular lymphoma 237 Primitive cutaneous follicular lymphoma (PCFL) 237 Large B‐cell lymphoma with IRF4 rearrangement 237 Mantle‐cell lymphoma (MCL) 237 Blastic mantle‐cell lymphoma (BMCL) 240 Leukemic non nodal mantle‐cell lymphoma 240 DLBCL not otherwise specified (DLBCLnos) 240 CD5(+) diffuse large cell lymphoma (CD5(+) DLBCL) 243 T‐cell/histiocyte‐rich B‐cell lymphoma (THRLBCL) 243 Primary DLBCL of the CNS (PCNSL) 244 Primary cutaneous DLBCL, “leg type” 244 EBV(+) DLBCLnos 244 DLBCL associated with chronic inflammation (PAL) 245 Fibrin associated DLBCL 245 Lymphomatoid granulomatosis (LYG) 245 Primary mediastinal B‐cell lymphoma (PMBCL) 245 Intravascular large B‐cell lymphoma (IVBCL) 246 ALK‐positive large cell lymphoma (ALK(+) LBCL) 246 Plasmablastic lymphoma (PBL) 247 Primary effusion lymphoma (PEL) 247 HHV8‐associated lymphoproliferative disorders 247 HHV8‐positive DLBCL 248 HHV8‐positive germinotropic lymphoproliferative disorder 248 Burkitt lymphoma (BL) 248 Burkitt leukemia with immature phenotype 250 Burkitt‐like lymphoma with 11q aberrations 251 High‐grade B‐cell lymphoma (HGBL) 251 Plasma cell neoplasms 251 Monoclonal gammopathies of undetermined significance (MGUS) 253 Multiple myeloma (MM) 253 Plasma cell leukemia (PCL) 257 Neoplastic diseases of mature T and NK cells 258 T‐cell prolymphocytic leukemia (T‐PLL) 258 T‐cell large granular lymphocytic leukemia (T‐LGL) 261 Chronic lymphoproliferative disorders of NK cells (CLPD‐NK/CNKL) 263 Aggressive NK‐cell leukemia (ANKL) 266 Adult T‐cell leukemia/lymphoma (ATLL) 266 Extranodal NK/T-cell lymphoma, “nasal type” (ENKTL) 269 Intestinal T‐cell lymphomas (ITCL) 270 Enteropathy‐associated T‐cell lymphoma (EATCL) 270 Monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) 272 Indolent gastro‐intestinal T lymphoproliferative disorder (indolent GI T‐LPD) 273 Hepatosplenic T‐cell lymphoma (HSTCL) 273 Subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) 275 Mycosis fungoides (MF) 275 Sezary syndrome (SS) 277 Primary cutaneous CD30(+) lymphoproliferative disorders 279 Lymphomatoid papulosis (LyP) 279 Primary cutaneous anaplastic T‐cell lymphoma (pcALCL) 279 Primary cutaneous peripheral T‐cell lymphoma (PTCL) 280 Primary cutaneous TCRγδ(+) T‐cell lymphoma (PCGD‐TCL) 280 Primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T‐cell lymphoma (PCAETL) 280 Primary cutaneous acral CD8(+) T‐cell lymphoma (PCATCL) 280 Primary cutaneous lymphoma of the medium/small CD4(+) T cells (PCSM‐TCL) 281 Peripheral T‐cell lymphoma, not otherwise specified (PTCLnos) 281 Nodal lymphomas of follicular T‐helper derivation 283 Angioimmunoblastic T‐cell lymphoma (AITL) 283 Follicular T‐cell lymphoma (FTCL) 285 Nodal PTCL with follicular T‐helper phenotype 285 Anaplastic large cell lymphoma ALK(+) (ALCL ALK(+)) 285 Anaplastic large cell lymphoma ALK(‐) (ALCL ALK(‐)) 288 Breast implant–associated anaplastic large cell lymphoma (biaALCL) 288 Hodgkin lymphomas 289 Classic Hodgkin lymphoma (CHL) 289 Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) 290 Neoplastic diseases of histiocytic and dendritic cells 291 Histiocytic sarcoma (HS) 292 Langerhans cell histiocytosis (LCH) 292 Indeterminate dendritic cell tumor (IDCT) 292 Interdigitating dendritic cell sarcoma (IDCS) 292 Follicular dendritic cell sarcoma (FDCS) 292 Erdheim–Chester disease (EDC) 292 3 Appendix 293 Acute leukemias not recognized by the 2017 WHO classification 294 Acute leukemia of myeloid/NK precursors (M/NK‐AL) 294 Acute leukemia of myeloid dendritic cells (MDCL) 294 Acute leukemia of Langerhans cells 294 Composite lymphomas 294 Hypereosinophilic syndrome (HES), lymphocyte variant 295 Indolent T lymphoblastic proliferations (iT‐LBP) 295 Polyclonal lymphocytoses of B lymphocytes 298 Persistent polyclonal B‐cell lymphocytosis (PPBL) 298 Persistent polyclonal CD5(+) B‐cell lymphocytosis 298 Persistent polyclonal B‐cell lymphocytosis, Japanese (hairy) variant 298 Polyclonal plasmacytoses 299 Small round (blue) cell tumors (SR(B)CT) 300 References 301 Index 429
About the author Claudio Ortolani is an expert in the area of diagnosis of hematological malignancies. Now retired, Dr Ortolani was Consultant in the Department of Clinical Pathology at Venice General Hospital, Venice, Italy. He is one of the founding members of the Italian Society for Cytometric Cell Analysis (ISCCA), of whose board he is currently a member. He has taught and lectured internationally on how to use flow cytometry to aid in diagnosing hematological diseases.
